Literature DB >> 11190414

Patient-Clinician choice in palliation of metastatic prostate cancer.

A V Kaisary1.   

Abstract

Palliation of patients with metastatic prostate cancer is based primarily on offering a form of androgen ablation. Each therapeutic modality has advantages and disadvantages. The decision with regards to the chosen option relies on thorough and open discussion between the treating urologist and the patient. Quality of life issues are increasingly an integral part of the treatment choice opted for. Thus, quality of life questionnaires should be incorporated into future clinical trial assessments and end-points.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11190414     DOI： 10.2165/00002512-200017050-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


  52 in total

1.  Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.

Authors:  G Chodak; R Sharifi; B Kasimis; N L Block; E Macramalla; G T Kennealey
Journal:  Urology       Date:  1995-12       Impact factor: 2.649

2.  Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.

Authors:  I Rosendahl; G M Kiebert; D Curran; B F Cole; J C Weeks; L J Denis; R R Hall
Journal:  Prostate       Date:  1999-02-01       Impact factor: 4.104

3.  Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up.

Authors: 
Journal:  Mol Urol       Date:  1999

4.  Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group.

Authors:  A O Turkes; W B Peeling; K Griffiths
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

5.  Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc Committee on Androcur Users.

Authors:  S Watanabe; S Yamasaki; A Tanae; I Hibi; T Honna
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

6.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

Authors: 
Journal:  Br J Urol       Date:  1997-02

7.  A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians.

Authors:  C L Bennett; G Chapman; A S Elstein; S J Knight; R B Nadler; R Sharifi; T Kuzel
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

8.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

Authors:  P Esper; F Mo; G Chodak; M Sinner; D Cella; K J Pienta
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

9.  A brief POMS measure of distress for cancer patients.

Authors:  D F Cella; P B Jacobsen; E J Orav; J C Holland; P M Silberfarb; S Rafla
Journal:  J Chronic Dis       Date:  1987

10.  A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

Authors:  C J Tyrrell; A V Kaisary; P Iversen; J B Anderson; L Baert; T Tammela; M Chamberlain; A Webster; G Blackledge
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.